Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
- First Posted Date
- 2024-12-02
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 316
- Registration Number
- NCT06711887
Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis
Phase 1
Recruiting
- Conditions
- Generalized Myasthenia Gravis
- First Posted Date
- 2024-11-26
- Last Posted Date
- 2025-05-14
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 15
- Registration Number
- NCT06704269
- Locations
- 🇺🇸
Wake Forest Univ School of Medicine, Winston-Salem, North Carolina, United States
🇺🇸Univ Cali Irvine ALS Neuromuscular, Orange, California, United States
🇺🇸Houston Methodist Hospital, Houston, Texas, United States
A Study to Evaluate Real-world Brolucizumab Effectiveness and Safety in Japanese Patients With Neovascular Age-related Macular Degeneration (nAMD)
Completed
- Conditions
- Neovascular Age-Related Macular Degeneration
- First Posted Date
- 2024-11-21
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 438
- Registration Number
- NCT06699914
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Therapy
Completed
- Conditions
- Chronic Myeloid Leukemia
- First Posted Date
- 2024-11-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 2043
- Registration Number
- NCT06692803
- Locations
- 🇺🇸
Novartis, East Hanover, New Jersey, United States
RWE,NIS,Prospective Study for the Effectiveness, Tolerability and Adherence of Asciminib in Saudi Arabia. (ASC4REAL)
Not yet recruiting
- Conditions
- Chronic Myelogenous Leukemia in Chronic Phase
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40
- Registration Number
- NCT06684964
A Real-world Study of the Safety of Hypertension Medication Therapy in Japanese Patients With Naïve Hypertension
Completed
- Conditions
- Hypertension
- First Posted Date
- 2024-11-12
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 40563
- Registration Number
- NCT06683768
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
Phase 1
Recruiting
- Conditions
- Progressive Multiple Sclerosis
- Interventions
- Biological: rapcabtagene autoleucel (YTB323)
- First Posted Date
- 2024-11-05
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT06675864
- Locations
- 🇨🇭
Novartis Investigative Site, Zuerich, Switzerland
Effectiveness of Early Intervention in Transfusion Independent Aplastic Anemia: a Retrospective Medical Claims Database Study
Completed
- Conditions
- Aplastic Anemia (AA)
- First Posted Date
- 2024-11-01
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 1603
- Registration Number
- NCT06669221
- Locations
- 🇯🇵
Novartis, Tokyo, Japan
Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous Formulation
Not yet recruiting
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2024-10-31
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT06668324
Psoriatic Disease and Related Manifestations; Real World Evidence in Brazilian Secukinumab Environment
Completed
- Conditions
- Psoriasis (PsO)Psoriatic Arthritis (PsA)
- First Posted Date
- 2024-10-30
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 232
- Registration Number
- NCT06666114
- Locations
- 🇧🇷
Novartis, Sao Paulo, Brazil
© Copyright 2025. All Rights Reserved by MedPath